1. Search Result
Search Result
Isoforms Recommended: IL-23
Results for "

IL23

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Screening Libraries

4

Peptides

16

Inhibitory Antibodies

1

Natural
Products

33

Recombinant Proteins

3

Isotope-Labeled Compounds

2

Antibodies

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10723

    Interleukin Related Inflammation/Immunology
    IL-23R inhibitor peptide-1 (comp 475) is an interleukin-23 receptor inhibitor, with an IC50 of 0.0069 μM .
    IL-23R inhibitor peptide-1
  • HY-P990217

    Interleukin Related Inflammation/Immunology
    Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonal antibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma .
    Anti-Mouse IL-23 p19 Antibody (G23-8)
  • HY-P11039

    Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 281
  • HY-P11038

    Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 105
  • HY-RS06740

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il23a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il23a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il23a Mouse Pre-designed siRNA Set A
    Il23a Mouse Pre-designed siRNA Set A
  • HY-RS06739

    Small Interfering RNA (siRNA) Interleukin Related Others

    IL23A Human Pre-designed siRNA Set A contains three designed siRNAs for IL23A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL23A Human Pre-designed siRNA Set A
    IL23A Human Pre-designed siRNA Set A
  • HY-RS06741

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il23a Rat Pre-designed siRNA Set A contains three designed siRNAs for Il23a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il23a Rat Pre-designed siRNA Set A
    Il23a Rat Pre-designed siRNA Set A
  • HY-RS06742

    Small Interfering RNA (siRNA) Others

    IL23R Human Pre-designed siRNA Set A contains three designed siRNAs for IL23R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL23R Human Pre-designed siRNA Set A
    IL23R Human Pre-designed siRNA Set A
  • HY-RS16795

    Small Interfering RNA (siRNA) Others

    Il23r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il23r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il23r Mouse Pre-designed siRNA Set A
    Il23r Mouse Pre-designed siRNA Set A
  • HY-RS23236

    Small Interfering RNA (siRNA) Others

    Il23r Rat Pre-designed siRNA Set A contains three designed siRNAs for Il23r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il23r Rat Pre-designed siRNA Set A
    Il23r Rat Pre-designed siRNA Set A
  • HY-P99256

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-174617

    mRNA Inflammation/Immunology
    Human IL23A mRNA encodes the human interleukin 23A (IL23A) protein, a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23A associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity.
    Human IL23A mRNA
  • HY-174616

    mRNA Inflammation/Immunology
    Human IL23R mRNA encodes the human interleukin 23 receptor (IL23R) protein, a subunit of the receptor for IL23A/IL23. IL23R pairs with the receptor molecule IL12RB1/IL12R beta1, and both are required for IL23A signaling.
    Human IL23R mRNA
  • HY-P99737

    LY­3074828

    Interleukin Related Inflammation/Immunology
    Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
    Mirikizumab
  • HY-P99485

    AMG 139; MEDI2070

    Interleukin Related Inflammation/Immunology
    Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
    Brazikumab
  • HY-P9931

    CNTO 1959

    Interleukin Related Inflammation/Immunology
    Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
    Guselkumab
  • HY-P99248

    Risankizumab rzaa; BI 655066; ABBV-066

    Interleukin Related Inflammation/Immunology
    Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
    Risankizumab
  • HY-P991275

    Interleukin Related Inflammation/Immunology
    CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
    CNTO4088
  • HY-P991276

    Interleukin Related Inflammation/Immunology
    FM-303 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system .
    FM-303
  • HY-150732

    IRAK Inflammation/Immunology
    IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease .
    IRAK4-IN-18
  • HY-150733

    IRAK Inflammation/Immunology
    IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease .
    IRAK4-IN-19
  • HY-P991277

    HS-20137

    Interleukin Related Inflammation/Immunology
    QX-004N (HS-20137) is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). QX-004N is promising for research of immune system diseases and diseases of digestive system .
    QX-004N
  • HY-163314S

    JAK Interleukin Related IFNAR Inflammation/Immunology
    Tyk2-IN-18-d3 (Compound 18) is a Tyk2 inhibitor with an IC50 value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .
    Tyk2-IN-18-d3
  • HY-P99486

    ABT-874

    Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-P991274

    Interleukin Related Inflammation/Immunology
    BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
    BMS-986010
  • HY-130243

    ROR Inflammation/Immunology
    RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo .
    RORγt Inverse agonist 6
  • HY-P10587

    JNJ-77242113; JNJ-2113; PN-235

    Interleukin Related STAT Inflammation/Immunology
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra
  • HY-151363

    IRAK Inflammation/Immunology
    IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-21
  • HY-151365

    IRAK Inflammation/Immunology
    IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-22
  • HY-P990781

    SM03

    CD22 NOD-like Receptor (NLR) Interleukin Related Integrin Neurological Disease Inflammation/Immunology
    Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation . Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
    Suciraslimab
  • HY-126252

    ROR Interleukin Related Inflammation/Immunology
    A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation .
    A-9758
  • HY-117287A

    BMS-986165 hydrochloride

    Interleukin Related JAK IFNAR Inflammation/Immunology
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition .
    Deucravacitinib hydrochloride
  • HY-101762

    JAK Phosphodiesterase (PDE) Inflammation/Immunology
    TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC50 of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .
    TyK2-IN-2
  • HY-126242S

    JAK IFNAR Interleukin Related Inflammation/Immunology
    Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .
    Tyk2-IN-7
  • HY-155830

    ME3183; PDE4-IN-14

    Phosphodiesterase (PDE) Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC50s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .
    Morcamilast
  • HY-168971

    CP-25

    IFNAR STAT TNF Receptor Interleukin Related CXCR JAK G Protein-coupled Receptor Kinase (GRK) Inflammation/Immunology
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model .
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-171591

    Salt-inducible Kinase (SIK) Interleukin Related TNF Receptor Infection
    SIK2-IN-4 (Compound 4) is a highly selective SIK1/2 inhibitor (IC50s 0.143 and 0.076 μM, respectively). SIK2-IN-4 reduces the phosphorylation of transcription coactivator 3 (CRTC3) by targeting SIK1/2, thereby regulating cAMP response element binding protein (CREB)-dependent transcriptional activity. SIK2-IN-4 inhibits the production of pro-inflammatory cytokines such as TNF (IC50: 0.11 µM), IL-12/23 p40 (IC50: 0.25 µM), and IL-23 (IC50: 0.47 µM), while inducing the expression of the anti-inflammatory cytokine IL-10. SIK2-IN-4 can be used to study intestinal inflammation and other chronic inflammatory diseases .
    SIK2-IN-4
  • HY-156466

    STAT Interleukin Related IFNAR Inflammation/Immunology
    QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
    QL-1200186
  • HY-P9909
    Ustekinumab
    3 Publications Verification

    CNTO-1275; L04AC05; TT-20

    Interleukin Related Inflammation/Immunology Cancer
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
    Ustekinumab
  • HY-P990057

    Interleukin Related Cancer
    Picankibart is a human-derived IgG1κ antibody targeting IL23A.
    Picankibart
  • HY-14644A
    Apilimod mesylate
    Maximum Cited Publications
    36 Publications Verification

    STA 5326 mesylate; LAM-002A; AIT-101 mesylate

    Interleukin Related PIKfyve Inflammation/Immunology Cancer
    Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.
    Apilimod mesylate
  • HY-14644
    Apilimod
    Maximum Cited Publications
    36 Publications Verification

    STA 5326; LAM-002A free base; AIT-101

    Interleukin Related PIKfyve Inflammation/Immunology Cancer
    Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.
    Apilimod
  • HY-15982
    APY0201
    4 Publications Verification

    PIKfyve Interleukin Related Inflammation/Immunology
    APY0201 is a potent PIKfyve inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P2 in the presence of in the presence of [ 33P]ATP with an IC50 of 5.2 nM. APY0201 also inhibits IL-12/IL-23 production.
    APY0201
  • HY-133552

    ROR Inflammation/Immunology
    RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC50 of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R
    RORγt Inverse agonist 10
  • HY-P991408

    TNF Receptor Interleukin Related IFNAR Inflammation/Immunology
    DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
    DLX-105
  • HY-131968

    JAK Cytochrome P450 Inflammation/Immunology
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .
    BMS-986202
  • HY-176535

    BBC0115

    Epigenetic Reader Domain Interleukin Related STAT Inflammation/Immunology
    KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
    KB-0118
  • HY-N10295

    Aryl Hydrocarbon Receptor Inflammation/Immunology
    Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4 + T cells and CD11b + macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA . Flavipin exhibits the DPPH free radical scavenging ability with IC50 value of 7.2 μM, and has potent α-glucosidase inhibition with IC50 value of 33.8 μM .
    Flavipin
  • HY-RS06763

    Small Interfering RNA (siRNA) Others

    IL37 Human Pre-designed siRNA Set A contains three designed siRNAs for IL37 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL37 Human Pre-designed siRNA Set A
    IL37 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: